Skip to content

Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients

Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00517114
Enrollment
200
Registered
2007-08-16
Start date
2005-01-31
Completion date
2008-12-31
Last updated
2013-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux, Laryngitis

Keywords

Reflux laryngitis

Brief summary

The purpose of this study is to evaluate the efficacy of rabeprazole (pariet) versus placebo in treating reflux laryngitis in Chinese patients. Patients who attend the voice clinic of Department of ENT, Queen Mary hospital with suspected reflux laryngitis will be recruited. A questionnaire will be administered by the research assistant of the Department of Medicine and ENT, Queen Mary hospital. A 12-week course of PPI versus placebo trial will be commenced and patients' symptoms and signs will be documented at 6-week and 12-week time. The study will finish after a 12-week course of rabeprazole.

Interventions

Sponsors

The University of Hong Kong
CollaboratorOTHER
Hospital Authority, Hong Kong
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* Ambulatory patients with age between 18-80 years old * Patients with newly presented laryngitis.

Exclusion criteria

* They were under 18 or over 80 years of age * Has significant concomitant medical disease * Pregnancy or lactating women * Chronic cough attributable to known chronic pulmonary or tracheobronchial disease * Previous glottal surgery, radiotherapy or malignancy * Acid suppressive therapy within 4 wk prior to recruitment * Pharyngo-laryngeal infection in the previous 3 months * Tracheal intubation in previous 12 months * Immunosuppression and use of inhaled corticosteroid

Design outcomes

Primary

MeasureTime frame
Symptoms assessment, quality of life.12 weeks

Secondary

MeasureTime frame
Compliance4 weeks
Adverse effects4 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026